In this review:
Brain volume loss correlates with long-term disability worsening
Brain volume loss with alemtuzumab: 4-year outcomes
MRI activity with alemtuzumab: 6 year follow-up in highly active RMMS patients, and…
…over 4 years following switch from IFNβ-1a
Rapid onset of ocrelizumab suppression of MRI activity
6-year clinical outcomes with alemtuzumab in treatment-naive patients, and…
…those with inadequate response to prior therapy
Onset to clinical efficacy with ocrelizumab
Natalizumab vs fingolimod & DMF: real-life experience
Efficacy of opicinumab in RRMS
Siponimod efficacy in secondary progressive multiple sclerosis
Please login below to download this issue (PDF)